Explore. Dosing.

 

Explore. Dosing.

One Tablet Once Daily

Dosing
Overview

This infographic is a comprehensive interactive application that allows you to explore the convenient dosing of Linagliptin (Trajenta®) - a key feature for the simplicity that Linagliptin (Trajenta®) offers to a broad range of patients with type 2 diabetes*1.

References Open Icon References Close Icon

* Indicated for use in adult T2D patients. Linagliptin (Trajenta®) is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.

  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
References Close Icon

Footnotes

* Indicated for use in adult T2D patients. Linagliptin (Trajenta®) is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.

  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.

5mg Always

Linagliptin (Trajenta®) offers convenience through one dose, once daily, always 5mg.*1 It is the only globally-available DPP4i that does not need to be dose adjusted.*1 Linagliptin (Trajenta®) is 5mg, once daily, independent of a type 2 diabetes patient's kidney function, hepatic function†, age‡, ethnicity, BMI, disease duration, or background therapy§.

References Open Icon References Close Icon

1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.

* Indicated for use in adult patients. Linagliptin (Trajenta®) is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.

† Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking.

‡ No dose adjustment is necessary based on age.

§ Combination therapies studied with linagliptin were: Linagliptin as add-on to metformin therapy; Linagliptin as add-on to a combination of metformin and sulphonylurea therapy; Linagliptin as add-on to a combination of metformin and empagliflozin; Linagliptin as add-on to insulin therapy.

References Close Icon

Footnotes

1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.

* Indicated for use in adult patients. Linagliptin (Trajenta®) is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.

† Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking.

‡ No dose adjustment is necessary based on age.

§ Combination therapies studied with linagliptin were: Linagliptin as add-on to metformin therapy; Linagliptin as add-on to a combination of metformin and sulphonylurea therapy; Linagliptin as add-on to a combination of metformin and empagliflozin; Linagliptin as add-on to insulin therapy.

Lowest Kidney Excretion Among DPP4i

Linagliptin (Trajenta®) is primarily excreted via a non-kidney route, with only 5% excreted via kidneys1. In contrast, other globally-available DPP4 inhibitors are primarily (=75%) excreted via kidneys2-5. As a result, Linagliptin (Trajenta®) does not need additional drug-related kidney function monitoring nor dose adjustment in patients with kidney impairment.1

References Open Icon References Close Icon Compare Kidney Excretion
  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  2. Sitagliptin (Januvia®) EMA Summary of Product Characteristics
  3. Vildagliptin (Galvus®) EMA Summary of Product Characteristics
  4. Alogliptin (Vipidia®) EMA Summary of Product Characteristics
  5. Saxagliptin (Onglyza®) EMA Summary of Product Characteristics
References Close Icon

Footnotes

  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  2. Sitagliptin (Januvia®) EMA Summary of Product Characteristics
  3. Vildagliptin (Galvus®) EMA Summary of Product Characteristics
  4. Alogliptin (Vipidia®) EMA Summary of Product Characteristics
  5. Saxagliptin (Onglyza®) EMA Summary of Product Characteristics
References Close Icon

Lowest Kidney Excretion Among DPP4i

Proportions of medication excreted via the kidney1-5

Kidney Excretion Across DPP4i References Open Icon
References Close Icon

Footnotes

  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  2. Sitagliptin (Januvia®) EMA Summary of Product Characteristics
  3. Vildagliptin (Galvus®) EMA Summary of Product Characteristics
  4. Alogliptin (Vipidia®) EMA Summary of Product Characteristics
  5. Saxagliptin (Onglyza®) EMA Summary of Product Characteristics

Most Convenient Dosing Schedule*1-5

As patients enter moderate or severe kidney impairment, or end stage kidney disease, the dose of many other DPP4 inhibitors must be adjusted, or in some cases discontinued. Not with Linagliptin (Trajenta®). One dose, always 5mg.

References Open Icon References Close Icon Compare Dosing Schedules

* Among globally-available DPP4 inhibitors: linagliptin, sitagliptin, saxagliptin, vildagliptin, alogliptin.

  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  2. Sitagliptin (Januvia®) EMA Summary of Product Characteristics
  3. Vildagliptin (Galvus®) EMA Summary of Product Characteristics
  4. Alogliptin (Vipidia®) EMA Summary of Product Characteristics
  5. Saxagliptin (Onglyza®) EMA Summary of Product Characteristics
References Close Icon

Footnotes

* Among globally-available DPP4 inhibitors: linagliptin, sitagliptin, saxagliptin, vildagliptin, alogliptin

  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  2. Sitagliptin (Januvia®) EMA Summary of Product Characteristics
  3. Vildagliptin (Galvus®) EMA Summary of Product Characteristics
  4. Alogliptin (Vipidia®) EMA Summary of Product Characteristics
  5. Saxagliptin (Onglyza®) EMA Summary of Product Characteristics
References Close Icon

Most Convenient Dosing Schedule*1-5

Required DPP4i dose with declining kidney function, as defined by SmPC

Dosing Schedules Across DPP4i References Open Icon
References Close Icon

Footnotes

  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  2. Sitagliptin (Januvia®) EMA Summary of Product Characteristics
  3. Vildagliptin (Galvus®) EMA Summary of Product Characteristics
  4. Alogliptin (Vipidia®) EMA Summary of Product Characteristics
  5. Saxagliptin (Onglyza®) EMA Summary of Product Characteristics
Start Simple Stay Simple

Start Simple,
Stay Simple

Linagliptin+Metformin (Trajenta Duo®) is a single-pill combination of linagliptin and metformin that is available in multiple metformin strengths for dosing flexibility1. For metformin-uncontrolled patients, you can start simple with Linagliptin+Metformin (Trajenta Duo®) 2.5mg BID and, should kidney function decline further*, continue with Linagliptin (Trajenta®) 5mg QD (once-daily), meaning the same total daily dose of linagliptin1-2. Start simple, stay simple.

References Open Icon References Close Icon Compare Dosing Schedules

* Linagliptin+Metformin (Trajenta Duo®) must not be used in patients with eGFR < 45 mL/min due to the active substance metformin. Linagliptin may be continued as a single entity tablet (Linagliptin (Trajenta®)) at the same total daily dose of 5mg if metformin is discontinued due to evidence of kidney impairment.

  1. Linagliptin + Metformin HCl (TRAJENTA DUO®) PH Prescribing Information. April 2021.
  2. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
References Close Icon

Footnotes

* Linagliptin+Metformin (Trajenta Duo®) must not be used in patients with eGFR < 45 mL/min due to the active substance metformin. Linagliptin may be continued as a single entity tablet (Linagliptin (Trajenta®)) at the same total daily dose of 5mg if metformin is discontinued due to evidence of kidney impairment.

  1. Linagliptin + Metformin HCl (TRAJENTA DUO®) PH Prescribing Information. April 2021.
  2. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
References Close Icon

Start Simple,
Stay Simple

Required DPP4i + metformin dose with declining kidney function, as defined by SmPC

 
Dosing Schedules Across DPP4i + Metformin References Open Icon
References Close Icon

Footnotes

  1. Linagliptin + Metformin HCl (TRAJENTA DUO®) PH Prescribing Information. April 2021.
  2. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  3. Metformin (Glucophage®) EMA Sumary of Product Characteristics
  4. Sitagliptin + Metformin (Janumet®) EMA Summary of Product Characteristics
  5. Saxagliptin + Metformin (Kombiglyze®) EMA Summary of Product Characteristics
  6. Vildagliptin + Metformin (Eucreas®) EMA Summary of Product Characteristics
  7. Alogliptin + Metformin (Vipdomet®) EMA Summary of Product Characteristics
doctor-writing-notes

Simplicity means...

Relying on a DPP4i that does not need to be dose adjusted

When you decide to use a DPP4i to lower HbA1C, you should rely on one that does not need to be dose adjusted. Linagliptin (Trajenta®) has a convenient dosing schedule, allowing confidence when treating a broad range of T2D patients1.

References Open Icon References Close Icon
  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
Close Modal

Footnotes

  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.

Boehringer Ingelheim (Philippines), Inc.
23rd Floor, BDO Towers Valero Bldg.,
8741 Paseo de Roxas, Bel-Air,
Makati City, Metro Manila
Phone +(632) 8867-0800
Email to us: 
BI.SKIES.ph@boehringer-ingelheim.com

10 Years of Simplicity

RIN Number: PC-PH-103188
Production Date: January 2023

Home Home Icon Dosing
Overview Dosing Overview Icon 5mg
Always Dosing 5mg Always Icon Kidney
Excretion Dosing Kidney Excretion Icon Dosing
Schedule Dosing Schedule Icon Linagliptin+
Metformin
(Trajenta Duo®) Dosing Linagliptin+Metformin (Trajenta Duo®) Icon Summary Dosing Summary Icon

Proportions of medication excreted via the kidney 1-5

References Close Icon
Kidney Excretion Across DPP4i
References Open Icon References Close Icon
  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  2. Sitagliptin (Januvia®) EMA Summary of Product Characteristics
  3. Vildagliptin (Galvus®) EMA Summary of Product Characteristics
  4. Alogliptin (Vipidia®) EMA Summary of Product Characteristics
  5. Saxagliptin (Onglyza®) EMA Summary of Product Characteristics

Required DPP4i dose with declining kidney function, as defined by SmPC

Close modal
Dosing Schedules Across DPP4i
References Open Icon References Close Icon
  1. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  2. Sitagliptin (Januvia®) EMA Summary of Product Characteristics
  3. Vildagliptin (Galvus®) EMA Summary of Product Characteristics
  4. Alogliptin (Vipidia®) EMA Summary of Product Characteristics
  5. Saxagliptin (Onglyza®) EMA Summary of Product Characteristics

Required DPP4i + metformin dose with declining kidney function, as defined by SmPC

References Close Icon
Dosing Schedules Across DPP4i + Metformin
References Open Icon References Close Icon
  1. Linagliptin + Metformin HCl (TRAJENTA DUO®) PH Prescribing Information. April 2021.
  2. Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.
  3. Metformin (Glucophage®) EMA Sumary of Product Characteristics
  4. Sitagliptin + Metformin (Janumet®) EMA Summary of Product Characteristics
  5. Saxagliptin + Metformin (Kombiglyze®) EMA Summary of Product Characteristics
  6. Vildagliptin + Metformin (Eucreas®) EMA Summary of Product Characteristics
  7. Alogliptin + Metformin (Vipdomet®) EMA Summary of Product Characteristics